BioSpace News Archive

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, announced that it has received positive toxicology results for AL002 in a good laboratory practices toxicology study using a transgenic mouse model of Alzheimer’s disease.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, reported results from several ongoing preclinical studies in the rare lysosomal diseases MPS-1, MPS-2, and MPS-6.

Alkermes plc announced the 2021 recipients of grants from the company’s signature Alkermes Inspiration Grants® program.

Sensient Technologies Corporation (NYSE: SXT) reported consolidated revenue of $335.8 million in this year’s second quarter compared to $323.1 million in last year’s second quarter.

HTG Molecular Diagnostics , Inc. today announced that, on July 13th and July 22nd, 2021 the Compensation Committee of the HTG Board of Directors granted inducement stock option awards to purchase an aggregate of 30,000 shares of common stock to two employees who have recently joined HTG.

Johnson & Johnson Vision today announced the global availability of the VERITAS Vision System, a next-generation phacoemulsification (phaco) system designed to address three critical areas: patient safety, surgeon efficiency and comfort.

Cortexyme, Inc. announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection.

Elekta (EKTA-B.ST) announced today that GenesisCare, a leading global provider of integrated cancer care, has ordered 27 Flexitron® brachytherapy afterloader systems, including service agreements

The report provides the trends prevailing in the global enteral nutrition market and the factors driving the market along with those that act as hindrances.

However, security and privacy issues, and unaddressed regulatory concerns restrain the market growth.